Plasma proteins in cancer

Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19

Glycosylation is the most common form of post-translational modification of proteins, critically affecting their structure and function. Using liquid chromatography and mass spectrometry for high-resolution site-specific quantification of glycopeptides coupled with high-throughput artificial intelligence-powered data processing, we analyzed differential protein glycoisoform distributions of 597 abundant serum glycopeptides and nonglycosylated peptides in 50 individuals who had been seriously ill with COVID-19 and in 22 individuals who had recovered after an asymptomatic course of COVID-19. As additional comparison reference phenotypes, we included 12 individuals with a history of infection with a common cold coronavirus, 16 patients with bacterial sepsis, and 15 healthy subjects without history of coronavirus exposure. We found statistically significant differences, at FDR < 0.05, for normalized abundances of 374 of the 597 peptides and glycopeptides interrogated between symptomatic and asymptomatic COVID-19 patients. Similar statistically significant differences were seen when comparing symptomatic COVID-19 patients to healthy controls (350 differentially abundant peptides and glycopeptides) and common cold coronavirus seropositive subjects (353 differentially abundant peptides and glycopeptides). Among healthy controls and sepsis patients, 326 peptides and glycopeptides were found to be differentially abundant, of which 277 overlapped with biomarkers that showed differential expression between symptomatic COVID-19 cases and healthy controls. Among symptomatic COVID-19 cases and sepsis patients, 101 glycopeptide and peptide biomarkers were found to be statistically significantly abundant. Using both supervised and unsupervised machine learning techniques, we found specific glycoprotein profiles to be strongly predictive of symptomatic COVID-19 infection. LASSO-regularized multivariable logistic regression and K-means clustering yielded accuracies of 100% in an independent test set and of 96% overall, respectively. Our findings are consistent with the interpretation that a majority of glycoprotein modifications observed which are shared among symptomatic COVID-19 and sepsis patients likely represent a generic consequence of a severe systemic immune and inflammatory state. However, there are glycoisoform changes that are specific and particular to severe COVID-19 infection. These may be representative of either COVID-19-specific consequences or susceptibility to or predisposition for a severe course of the disease. Our findings support the potential value of glycoproteomic biomarkers in the biomedical understanding and, potentially, the clinical management of serious acute infectious conditions.

Glycosylation and cancer: moving glycomics to the forefront

There is a long research history of studying the function of glycosylation in relation to the development and progression of different types of cancer. The technological advances of the "omic" have in the last decade have afforded many new opportunities and approaches for studying the cancer glycome. A collection of research articles has been assembled that collectively summarize the progress in this area for each type of major O-linked and N-linked glycan species and other classes of glycans, as well as what is known about specific glycans associated with individual types of cancer (brain, breast, colon, liver, lung, ovarian, pancreatic, prostate). These chapters also include descriptions of the latest cutting-edge technologies that have been developed recently for cancer glycomic studies. An introduction to these topics and highlights of emerging areas of research opportunity for cancer glycomics are presented. This includes the development of new glycomics-based cancer biomarkers and therapeutic targets, as well as different integrated cancer "omics" strategies.

Isolation and characterization of a wheat germ agglutinin-binding glycoprotein from B16 mouse melanoma cells

Cells of B16 mouse melanoma grown in serum-free medium in the presence of [3H]glucosamine secreted or shed labeled glycoproteins. A wheat germ agglutinin-binding glycoprotein was isolated that accounted for 37% of the total [3H]glucosamine incorporated; it had a molecular weight of approximately 50,000 and was absent in less-tumorgenic wheat germ agglutinin (isolectin I)-resistant variants of the cells. The glycoprotein contained approximately 25% of serine and threonine plus equimolar amounts of glucosamine and galactosamine, indicating both N- and O-linked oligosaccharide chains. Neuraminidase treatment released approximately 60% of the glycoprotein's 3H radioactivity as N-acetylneuraminic acid. The sialoglycoprotein did not, but the desialylated species did, bind (97%) to ricin-Sepharose, suggesting the presence of terminal sialic acid and penultimate galactose residues in most of the saccharide units. Alkaline borohydride released 61% of the glycoprotein's radioactivity as oligosaccharide alcohols that were mainly tetrasaccharides (75%) with some branched trisaccharides (10%) from the O-linked structures. Hydrazinolysis and analysis of the alkaline borohydride-resistant portion of the glycoprotein indicated the presence of mainly triantennary, complex-type structures (N-linked) containing three sialic acids residues plus L-fucose. Serial lectin-affinity chromatography of the hydrazine-released saccharides with concanavalin A-agarose, pea lectin-agarose, L-PHA-agarose, and E-PHA-agarose, indicated the absence of high-mannose or hybrid-type structures and further confirmed the presence of triantennary, complex-type units.

Sialic acid metabolism in rats undergoing chemically-induced mammary gland carcinogenesis in specific dietary states

The enzymes responsible for the activation, transfer and hydrolysis of sialic acids were investigated in female rats with mammary adenocarcinomas induced by administration of a single oral dose (10 mg) of 7,12-dimethylbenz[alpha]anthracene. The carcinogenic process was modulated by the levels and degree of unsaturation of the dietary lipids. Tumor incidence was highest in rats fed a diet containing 20% corn oil, intermediate with 18% coconut oil plus 2% linoleic acid, and lowest in the group receiving a diet with 2% linoleic acid. Sialyltransferase and CMP-N-acetylneuraminic acid synthetase activities were higher in tumors than in control mammary glands. Neuraminidase activity, on the other hand, was higher in control tissue than in tumors. In addition to these tumor-related effects, comparison of the enzyme levels in mammary tissues from control animals of the 3 dietary groups revealed the presence of diet-related effects on sialic acid metabolism. In the livers of tumor-bearing rats, only minor changes of enzyme activities were detected.

Mechanism of impaired glucose tolerance in patients with neoplasia

The disappearance rate (k) of i.v. glucose was measured in cachectic and non-cachectic cancer patients and tumour-free controls. The respective k values were found to be 1.06 +/- 0.27 (mean +/- s.d.), 1.64 +/- 0.34 and 1.63 +/- 0.23. Of the other parameters measured, only plasma albumin level was found to vary significantly amongst the 3 categories, the mean level being the lowest in cachectic cancer patients. The means of total plasma protein, fasting blood glucose and plasma liver enzyme concentrations were similar in the 3 groups. Glucagon, a potent insulin secretogogue, failed to augment the fasting insulin level in cachectic but did so in non-cachectic cancer patients. Taken together, the findings suggest that the reduced glucose tolerance in patients with neoplasia is due to impairment of insulin release exhibited predominantly by ill-nourished advanced cancer patients having a moderate to sever degree of hypoalbuminemia.